Healthy Extracts (HYEX) Total Non-Current Liabilities (2015 - 2025)
Healthy Extracts' (HYEX) quarterly Total Non-Current Liabilities came in at $2.1 million in Q4 2025, up 235.58% year-on-year from $627847.0 in Q4 2024, and up 120.42% quarter-over-quarter from $955856.0 in Q3 2025.
Healthy Extracts (HYEX) Total Non-Current Liabilities (2015 - 2025) Analysis & Trends
Healthy Extracts' Total Non-Current Liabilities history runs 11 years deep, the most recent figure standing at $2.1 million for Q4 2025.
- On a quarterly basis, Total Non-Current Liabilities rose 235.58% year-over-year to $2.1 million in Q4 2025; TTM through Dec 2025 was $2.1 million, a 235.58% increase from a year earlier, with the FY2025 full-year figure at $2.1 million, up 235.58% from the prior year.
- Total Non-Current Liabilities climbed to $2.1 million in Q4 2025 per HYEX's latest filing, from $955856.0 in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $2.9 million in Q4 2021 and bottomed at -$910779.0 in Q1 2024.
- The 5-year median for Total Non-Current Liabilities is $1.4 million (2023), against an average of $1.3 million.
- Across the five-year window, Total Non-Current Liabilities soared 1780.25% in 2021 and sank 1279.58% in 2023, its largest moves.
- Year by year, Total Non-Current Liabilities stood at $2.9 million in 2021, then dropped by 10.56% to $2.6 million in 2022, then retreated by 5.56% to $2.5 million in 2023, then tumbled by 74.69% to $627847.0 in 2024, then surged by 235.58% to $2.1 million in 2025.
- Per Business Quant, the three latest HYEX Total Non-Current Liabilities figures stand at $2.1 million (Q4 2025), $955856.0 (Q3 2025), and $1.2 million (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 14.92 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 18.28 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 33.47 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 599.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 20.09 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 1.24 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 6.26 Bn |
| 10 | Healthy Extracts | 14.70 Mn | 14.56 Mn | 957,429.00 | 2.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.11 Mn |
| Sep 30, 2025 | 955,856.00 |
| Jun 30, 2025 | 1.16 Mn |
| Mar 31, 2025 | 1.53 Mn |
| Dec 31, 2024 | 627,847.00 |
| Sep 30, 2024 | 1.02 Mn |
| Jun 30, 2024 | -736,623.00 |
| Mar 31, 2024 | -910,779.00 |
| Dec 31, 2023 | 2.48 Mn |
| Sep 30, 2023 | 1.39 Mn |
| Jun 30, 2023 | 1.48 Mn |
| Mar 31, 2023 | -186,919.00 |
| Dec 31, 2022 | 2.63 Mn |
| Sep 30, 2022 | 1.53 Mn |
| Jun 30, 2022 | 1.74 Mn |
| Mar 31, 2022 | -13,549.00 |
| Dec 31, 2021 | 2.94 Mn |
| Sep 30, 2021 | 2.14 Mn |
| Jun 30, 2021 | 2.62 Mn |
| Mar 31, 2021 | 634,057.00 |